Sponsored

Editor’s Note: Our friend Louis Navellier is a regular guest at Mar-a-Lago, President Trump’s private residence in Palm Beach Florida. He’s also one of America’s top tech investors, managing a $1.1 billion portfolio – including $358 million in AI stocks. (He recommended Nvidia to his followers before it soared 44,000%.) In addition, he predicted the Dot-Com crash. He called Google’s rise. And now he has a shocking warning about the SpaceX IPO that all Americans deserve to hear. See below for details.

---

SpaceX is headed toward what could be a $1.6 trillion IPO – the biggest in history.

It could make Elon the world’s first trillionaire.

And it would likely create countless new millionaires and billionaires, too.

But Elon’s dreams of dominating space and AI could soon come crashing down.

Because Donald Trump has recently signed Executive Order (#14363).

While the mainstream media obsesses over this historic IPO…

Not only could it render SpaceX’s AI technology obsolete…

It could trigger a $100 trillion “reset” of the AI markets in America.

How could it disrupt the biggest IPO in history in the process?

How could it send shares of one obscure AI stock soaring?

And how could you turn this into a massive opportunity, starting now?

Simply click here for my brand-new presentation revealing all the details.

I even reveal the name and ticker of one company poised to profit, for free.

Fair warning: This information is very time sensitive. I could take it down at any time.

So please don’t delay. Inform yourself now, before the big IPO.

Louis Navellier
Senior Investment Analyst, InvestorPlace

P.S. I consider this the biggest prediction in my 40-year career.

Trump’s executive order could send shockwaves throughout the AI economy. As you’ll see, he’s building a new AI technology 283 trillion times more powerful than Elon’s. It may sound crazy. But it’s 100% true. And understanding exactly what’s coming could save you a lot of money in 2026… while getting you in early on the biggest AI revolution ever.

---

This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. 

FEATURED

BIIB Is Quiet. The Options Flow Is Not.

Analyst Targets

• UBS – Buy | Price Target: $225 (upgraded April 2026)
• Goldman Sachs – Buy | Price Target: $225 (raised from $197)
• B of A Securities – Buy | Price Target: $260
• Jefferies – Buy | Price Target: $190
• Truist Securities – Hold | Price Target: $190
• Mizuho – Buy | Price Target: $207
• Consensus (48 analysts) – Median target: $190 | Range: $143 to $260

Biogen isn’t moving much on the surface. The stock has been grinding in a tight band near $195, off its 52-week high of around $206, with no explosive headline driving volume. And yet, underneath that calm, the options market is telling a different story entirely.

Institutional call blocks are building open interest in the July $230 and $240 strike brackets – significantly out-of-the-money relative to current price, and not the kind of positioning that comes from retail guesswork. This is event-driven flow, disconnected from the broader macro environment, and it’s pointing at something specific: a concentrated pipeline catalyst window that Biogen has telegraphed for the middle and back half of 2026.

What’s interesting is just how much is converging at once.

Company Profile

Biogen is a Cambridge, Massachusetts-based biopharma company focused on neurological, rare, and autoimmune diseases. Its commercial portfolio spans multiple sclerosis (VUMERITY, TYSABRI, AVONEX), spinal muscular atrophy (SPINRAZA), Friedreich’s ataxia (SKYCLARYS), ALS (QALSODY), and – most critically for long-term growth positioning – Alzheimer’s disease through its co-commercialization partnership with Eisai on LEQEMBI.

The MS franchise, while still the largest revenue contributor at roughly 40% of total sales, is under sustained pressure from biosimilar competition and newer branded alternatives. Biogen’s growth thesis now rests almost entirely on whether its pipeline can replace that declining base – and 2026 is the year where the first major answers arrive.

The Recent Numbers

Q1 2026 results – reported April 29 – came in materially ahead of expectations across every key metric.

• Total Revenue: $2.48B vs. estimates of $2.30B – a beat of approximately $177M
• Non-GAAP EPS: $3.57 vs. estimates of $3.07 – a $0.50 beat
• GAAP EPS: $2.15, up 31% year-over-year
• Growth Products Revenue: $851M, up 12% year-over-year
• LEQEMBI Revenue: $168M, up 74% year-over-year
• SKYCLARYS Revenue: $151M globally, up 22% year-over-year
• Operating Cash Flow: $645.5M for the quarter
• Cash on Hand: $3.38B as of March 31, 2026

Shares moved roughly 6% higher the day after results. Management confirmed full-year 2026 non-GAAP EPS guidance of $14.25 to $15.25, with the range reflecting a roughly $0.80 per share impact from anticipated acquired IPR&D charges in Q2. The Q2 charge is already known – it’s related to the pending $5.6B Apellis acquisition, which Biogen is funding with existing cash plus approximately $2B in new borrowings.

Slight tangent, but it matters: the Apellis deal adds SYFOVRE and EMPAVELI to Biogen’s rare disease and immunology portfolio, and management has explicitly stated it expects the transaction to be accretive to revenue growth beginning in 2027. That’s a longer-dated catalyst the options market may also be pricing in at the margin.

Why the Options Flow Is Moving Now

The call skew building in July brackets isn’t random. It lines up almost precisely with the pipeline readout window Biogen and multiple Wall Street firms have publicly flagged. Three programs are converging on the same general timeframe:

• BIIB080 (Alzheimer’s/Tau) – Phase 2 CELIA data expected by mid-2026. An antisense oligonucleotide targeting tau, which received FDA Fast Track designation in April 2025. The Phase 1b trial showed encouraging tau reduction. If this POC readout holds, it would validate a genuinely novel mechanism in Alzheimer’s disease.
• BIIB122 (Parkinson’s) – Phase 2b LUMA study, fully enrolled as of early 2025, with data readout expected in 2026. Developed with Denali Therapeutics, this LRRK2 inhibitor program targets the most common genetic cause of Parkinson’s disease.
• Litifilimab (Lupus) – Phase 3 data in systemic lupus erythematosus expected Q4 2026, with the drug already holding FDA Breakthrough Therapy Designation for cutaneous lupus. Royalty Pharma committed up to $250M in development funding behind it.

UBS, in upgrading the stock to Buy in late April with a $225 target, specifically cited BIIB080 tau data this summer as the near-term upside driver. Goldman Sachs raised its target to $225 from $197. Jefferies initiated at Buy, pointing to the stock trading at roughly 9 times expected 2026 earnings – a steep discount to peer multiples of 13 to 29 times.

The part people skip: this kind of multi-catalyst convergence in a single window doesn’t happen often in large-cap biotech. Institutions are not waiting until the data arrives to build positions.

The Strategy: Calendar Spreads

The options positioning isn’t just directional call-buying. Smart money accounts are layering in Calendar Spreads – selling a short-dated call and simultaneously buying a longer-dated call at the same strike. The mechanics matter here: by selling the near-term contract, the trader collects premium that offsets the cost of the longer-dated position. The result is a lower net debit to get exposure to a multi-week or multi-month catalyst window.

This approach is particularly well-suited to BIIB’s current situation. The stock isn’t expected to make a large immediate move – it’s expected to move on data. Calendar spreads let sophisticated accounts hold positioning through the waiting period at a reduced cost, then potentially benefit from an acceleration in implied volatility and stock movement as the readout approaches. It’s not a bet on tomorrow. It’s a bet on a specific window.

Macro and Sector Context

Biotech in general is not being driven by macro right now. Rate expectations are relatively stable, and sector rotation into risk assets has been selective. What’s driving individual biotech names is precisely what’s driving BIIB’s options flow: binary events with large potential outcomes that are independent of the S&P’s daily behavior.

Within that context, Biogen occupies an unusual position. The MS franchise decline has compressed the multiple to the point where Jefferies argues the stock is trading at near no-pipeline value. That’s either a value trap or a coiled spring, depending entirely on what the next 18 months of data produce. The options market appears to have a view.

On the competitive side, LEQEMBI continues to face pressure from Eli Lilly’s Kisunla in Alzheimer’s, but Biogen reported that LEQEMBI maintains market leadership by total patient share in the U.S., Japan, and China as of Q1 2026. The FDA’s acceptance of a supplemental BLA for the subcutaneous autoinjector (LEQEMBI IQLIK) – with a PDUFA date of May 24, 2026 – adds another near-term regulatory milestone to the calendar.

Bull / Base / Bear

• Bull: BIIB080 POC data shows meaningful tau reduction with a clean safety profile, validating the mechanism and lifting sentiment across the Alzheimer’s franchise. LEQEMBI IQLIK subcutaneous approval expands patient access. Litifilimab Phase 3 enrolls on schedule toward H2 readout. Stock re-rates toward $225 to $260 range as the pipeline discount compresses. Calendar spreads in July calls move into meaningful profit.
• Base: BIIB080 data is mixed – tau reduction confirmed but clinical correlation unclear, pushing the program into further study. LEQEMBI continues steady commercial growth. Litifilimab data lands on schedule but market waits for more complete Phase 3 results. Stock holds in the $185 to $210 range. Options flow captures elevated IV around the readout but gains are modest.
• Bear: BIIB080 fails to show meaningful clinical signal, rekindling pipeline credibility concerns. Apellis integration costs exceed expectations. MS franchise declines accelerate faster than growth products can offset. Stock tests $150 to $160 support levels. July call brackets expire worthless.

Technical Overlay

BIIB has recovered significantly off its 52-week low of $121. The stock is now consolidating in the $190 to $205 zone, having peaked near $206 earlier in the year. Short and long-term moving averages are constructive – buy signals from both, with the short-term average above the long-term average as of early June. Support sits at approximately $194 and $191. A break below $191 would be technically meaningful and warrant reassessment.

The July $230 and $240 call strikes sit well above current price – roughly 18% to 23% out of the money. For those strikes to be in play by expiration, BIIB would need either a significant fundamental catalyst or a sustained re-rating of the multiple. The institutional flow building open interest there is not positioned for a gradual drift. It’s positioned for a move.

What to Watch

• BIIB080 Phase 2 CELIA tau data – expected mid-2026; this is the most immediate binary event
• LEQEMBI IQLIK PDUFA date (May 24, 2026) – subcutaneous approval would expand addressable patient base meaningfully
• BIIB122 Parkinson’s readout timing – any acceleration or delay in the 2026 window will move the stock
• Litifilimab Phase 3 SLE data – Q4 2026; Breakthrough Therapy Designation adds regulatory credibility
• Apellis acquisition close – expected to add SYFOVRE and EMPAVELI to portfolio; integration commentary in Q2 earnings will matter
• MS franchise revenue trajectory – continued erosion in legacy products remains the primary ongoing headwind
• Next earnings: July 30, 2026

Bottom Line

Biogen’s stock price is a function of one central question: does the pipeline deliver? The multiple sclerosis decline is known, modeled, and largely priced in. What isn’t priced in – at least not fully – is a scenario where BIIB080, BIIB122, and litifilimab each generate positive data within the same 12-month window. That’s what the institutional options flow appears to be betting on.

The calendar spread structure being deployed is deliberate. It suggests these accounts aren’t certain about timing, but they are certain about direction. They’re reducing cost to hold positioning through a defined catalyst period rather than abandoning the trade because the exact date is uncertain.

At roughly 13 times forward earnings and trading well below the peer group multiple, BIIB doesn’t need all three programs to succeed. It may only need one. The question is which one arrives first – and whether the stock waits for confirmation before moving.

For informational purposes only.